<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Estimated comparative daily doses for inhaled glucocorticoids in children</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Estimated comparative daily doses for inhaled glucocorticoids in children</h1>
<div class="graphic"><div class="figure"><div class="ttl">Estimated comparative daily doses for inhaled glucocorticoids in children</div><div class="cntnt"><table cellspacing="0"><colgroup width="34%"></colgroup><colgroup span="6" width="11%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1" rowspan="2">Drug</td> <td class="subtitle1" colspan="2">Low daily dose</td> <td class="subtitle1" colspan="2">Medium daily dose</td> <td class="subtitle1" colspan="2">High daily dose</td> </tr> <tr class="divider_bottom divider_top"> <td class="subtitle2">Child 0 to 4</td> <td class="subtitle2">Child 5 to 11</td> <td class="subtitle2">Child 0 to 4</td> <td class="subtitle2">Child 5 to 11</td> <td class="subtitle2">Child 0 to 4</td> <td class="subtitle2">Child 5 to 11</td> </tr> <tr class="divider_bottom divider_top"> <td> <p>Beclomethasone HFA</p> <p class="indent1">40 or 80 mcg/puff</p> </td> <td>NA</td> <td>40 mcg/puff - 1 to 2 puffs twice per day</td> <td>NA</td> <td> <p>40 mcg/puff - 2 to 4 puffs twice per day</p> 80 mcg/puff - 1 to 2 puffs twice per day</td> <td>NA</td> <td>80 mcg/puff - 3 to 4 puffs twice per day</td> </tr> <tr class="divider_bottom"> <td> <p>Budesonide DPI* (breath activated)</p> <p class="indent1">90 or 180 mcg/inhalation</p> </td> <td>NA</td> <td>90 mcg/inhalation - 1 to 2 inhalations twice per day</td> <td>NA</td> <td>180 mcg/inhalation - 1 to 2 inhalations twice per day</td> <td>NA</td> <td>180 mcg/inhalation - 3 to 4 inhalations twice per day</td> </tr> <tr class="divider_bottom"> <td> <p>Budesonide nebulization suspension<sup>¶</sup></p> <p class="indent1">0.25 mg/2 mL, 0.5 mg/2 mL, or 1 mg/2 mL</p> </td> <td>0.25 to 0.5 mg once daily or as 2 divided doses</td> <td>0.5 mg once daily or as 2 divided doses</td> <td>0.75 to 1 mg once daily or as 2 or 3 divided doses</td> <td>1 mg once daily or as 2 divided doses</td> <td>1.25 to 2 mg once daily or as 2 divided doses</td> <td>2 mg once daily or as 2 divided doses</td> </tr> <tr class="divider_bottom"> <td> <p>Ciclesonide HFA<sup>Δ</sup></p> <p class="indent1">80 or 160 mcg/puff</p> </td> <td>NA</td> <td>80 mcg/puff - 1 to 2 puffs once daily</td> <td>NA</td> <td>80 mcg/puff - 3 to 4 puffs once daily</td> <td>NA</td> <td> <p>80 mcg/puff - 5 to 6 puffs once daily or as 2 divided doses</p> 160 mcg/puff - 3 puffs once daily or as 2 divided doses</td> </tr> <tr class="divider_bottom"> <td> <p>Fluticasone HFA<sup>◊</sup></p> <p class="indent1">44, 110, or 220 mcg/puff</p> </td> <td>44 mcg/puff - 2 puffs twice per day<sup>◊</sup></td> <td>44 mcg/puff - 1 to 2 puffs twice per day</td> <td> <p>44 mcg/puff - 2 to 4 puffs twice per day</p> 110 mcg/puff - 1 puff in AM and 2 puffs in PM</td> <td> <p>44 mcg/puff - 2 to 4 puffs twice per day</p> 110 mcg/puff - 1 puff in AM and 2 puffs in PM</td> <td> <p>110 mcg/puff - 2 puffs twice per day</p> 220 mcg/puff - 1 puff twice per day</td> <td> <p>110 mcg/puff - 2 puffs twice per day</p> 220 mcg/puff - 1 puff twice per day</td> </tr> <tr class="divider_bottom"> <td> <p>Fluticasone DPI (breath activated)<sup>§</sup></p> <p class="indent1">50, 100, or 250 mcg/inhalation</p> </td> <td>NA</td> <td>50 mcg/inhalation - 1 to 2 inhalations twice per day</td> <td>NA</td> <td> <p>50 mcg/inhalation - 3 to 4 inhalations twice per day</p> 100 mcg/inhalation - 1 inhalation in AM and 2 inhalations in PM to 2 inhalations twice per day</td> <td>NA</td> <td> <p>100 mcg/inhalation - 2 inhalations in AM and 3 inhalations in PM</p> 250 mcg/inhalation - 1 inhalation twice per day</td> </tr> <tr class="divider_bottom"> <td> <p>Mometasone aerosol DPI (breath activated)*</p> <p class="indent1">110 or 220 mcg/inhalation</p> </td> <td>NA</td> <td>110 mcg/inhalation - 1 inhalation once daily</td> <td>NA</td> <td>110 mcg/inhalation - 2 to 3 inhalations once daily</td> <td>NA</td> <td> <p>110 mcg/inhalation - 4 inhalations once daily or 2 inhalations twice per day</p> 220 mcg/inhalation - 2 inhalations once daily or 1 inhalation twice per day</td> </tr> <tr> <td> <p>Mometasone HFA MDI</p> <p class="indent1">50, 100, or 200 mcg/puff</p> </td> <td>NA</td> <td>50 mcg/puff - 1 puff once or twice per day</td> <td>NA</td> <td> <p>50 mcg/puff - 2 to 3 puffs twice per day</p> 100 mcg/puff - 1 puff twice per day</td> <td>NA</td> <td> <p>100 mcg/puff - 2 puffs twice per day</p> 200 mcg/puff - 1 inhalation twice per day</td> </tr> </tbody></table></div><div class="graphic_lgnd">Some doses may be outside approved package labeling, especially in the high-dose range. Doses shown and strengths (ie, mcg per puff or inhalation) are based upon product descriptions approved in the United States, which may differ from how strengths are described for products available in other countries. Consult local product information before use.</div><div class="graphic_footnotes">HFA: hydrofluoroalkane; NA: not approved and no data available for this age group; DPI: dry-powder inhaler; AM: in morning; PM: in evening; US FDA: US Food and Drug Administration; MDI: metered-dose inhaler.<br/>* Contains milk protein.<br/>¶ Budesonide suspension is compatible with albuterol, ipratropium, and levalbuterol nebulizer solutions in the same nebulizer. Use only jet nebulizers as ultrasonic nebulizers are ineffective for suspensions.<br/>Δ Ciclesonide is not approved by the US FDA for use in children under 12. It is approved for use in children 6 years of age and older in Canada, some European countries, and elsewhere.<br/><span class="lozenge">◊</span> For fluticasone HFA, the low dose for children &lt;4 years is higher than for children 5 to 11 years of age due to lower dose delivered with facemask and data on efficacy in young children.<br/>§ Contains lactose.</div><div class="graphic_reference">Data from:

<ol>
<li>National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</li>
<li>Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Updated 2012. Available at <a href="http://www.ginasthma.org" target="_blank">www.ginasthma.org</a>.</li>
</ol></div><div id="graphicVersion">Graphic 68517 Version 18.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
